Search

01/10/2024 Carcinoma Following Neoadjuvant Chemotherapy Oncologic Outcomes in Patients with Residual Upper Tract Urothelial
Fletcher, SA, Pallauf, M, Watts, EK, Lombardo, KA, Campbell, JA, Rezaee, ME, Rouprêt, M, Boorjian, SA, Potretzke, AM, Roshandel, MR, Ploussard, G, Djaladat, H, Ghoreifi, A, Mari, A, Campi, R, Khene, ZE, Raman, JD, Kikuchi, E, Rink, M, Abdollah, F, Boormans, JL, Fujita, K, D'Andrea, D, Soria, F, Breda, A, Hoffman-Censits, J, Mcconkey, DJ, Shariat, SF, Pradere, B, Singla, N. Carcinoma Following Neoadjuvant Chemotherapy Oncologic Outcomes in Patients with Residual Upper Tract Urothelial. European Urology Oncology. 2024; 7(5)DOI:10.1016/j.euo.2024.01.010. PMID:38262800. IF:9.300(Q1/1D).
01/10/2024 Primary pyeloplasty for uretero-pelvic obstruction in the USA adult population with or without double-J indwelling ureteral stents Insurance claims data on contemporary time to removal trends, perioperative complications, health care costs, and re-intervention rates
Del Giudice, F, Han, DH, Tresh, A, Li, SF, Basran, S, Asero, V, Scornajenghi, CM, Carino, D, Corvino, R, Ferro, M, Crocetto, F, Pradere, B, Gallioli, A, Krajewski, W, Nowak, L, Laszkiewicz, J, Szydelko, T, Rocco, B, Sighinolfi, MC, De Berardinis, E, Kam, J, Nair, R, Chung, BI. Primary pyeloplasty for uretero-pelvic obstruction in the USA adult population with or without double-J indwelling ureteral stents Insurance claims data on contemporary time to removal trends, perioperative complications, health care costs, and re-intervention rates. Minerva Urology And Nephrology. 2024; 76(5)DOI:10.23736/S2724-6051.24.05834-8. PMID:39320251. IF:4.200(Q1/2D).
27/09/2024 Young age and adequate BCG are key factors for optimal BCG treatment efficacy in non-muscle-invasive bladder cancer
Liu, K, Nicoletti, R, Zhao, HD, Chen, X, Wu, HW, Leung, CH, D'Andrea, D, Laukhtina, E, Soria, F, Gallioli, A, Wroclawski, ML, Castellani, D, Gauhar, V, Rivas, JG, Enikeev, D, Gontero, P, Shariat, SF, Chiu, PKF, Ng, CF, Teoh, JYC. Young age and adequate BCG are key factors for optimal BCG treatment efficacy in non-muscle-invasive bladder cancer. WORLD JOURNAL OF UROLOGY. 2024; 42(1)DOI:10.1007/s00345-024-05218-4. PMID:39331198. IF:2.900(Q2/3D).
25/09/2024 Clinical Significance of Tumor Location for Ureteroscopic Tumor Grading in Upper Tract Urothelial Carcinoma
Katayama, S, Pradere, B, Grossman, NC, Potretzke, AM, Boorjian, SA, Ghoreifi, A, Daneshmand, S, Djaladat, H, Sfakianos, JP, Mari, A, Khene, ZE, D'andrea, D, Hayakawa, N, Fujita, K, Heindenreich, A, Raman, JD, Roumiguié, M, Abdollah, F, Breda, A, Fontana, M, Rouprêt, M, Margulis, V, Karakiewicz, PI, Araki, M, Nasu, Y, Shariat, SF. Clinical Significance of Tumor Location for Ureteroscopic Tumor Grading in Upper Tract Urothelial Carcinoma. JOURNAL OF ENDOUROLOGY. 2024; 38(11)DOI:10.1089/end.2024.0335. PMID:39264866. IF:2.800(Q2/3D).
11/09/2024 Cryotherapy versus radical prostatectomy as a salvage treatment for radio-recurrent prostate cancer
Rivas, JG, Taratkin, M, Azilgareeva, C, Morozov, A, Laso, S, Enikeev, D, Sierra, JM, Schelkunova, K, Sanguedolce, F, Breda, A, Govorov, A, Vasilyev, A, Cepeda, M, Lusuardi, L, Pallauf, M, Celia, A, Silvestri, T, Fiori, C, Fernández, E, Martínez-Salamanca, JI, Barret, E. Cryotherapy versus radical prostatectomy as a salvage treatment for radio-recurrent prostate cancer. WORLD JOURNAL OF UROLOGY. 2024; 42(1)DOI:10.1007/s00345-024-05199-4. PMID:39259304. IF:2.900(Q2/3D).
01/09/2024 Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial
Garcia-Ruiz, A, Macarro, C, Zacchi, F, Morales-Barrera, R, Grussu, F, Casanova-Salas, I, Sanguedolce, F, Gonzalez, M, Cresta-Morgado, P, de Albert, M, Garcia-Bennett, J, Marmolejo, D, Planas, J, Roche, S, Mast, R, Zatse, C, Piulats, JM, Herrera-Imbroda, B, Regis, L, Agundez, L, Olmos, D, Calvo, N, Escobar, M, Carles, J, Mateo, J, Perez-Lopez, R. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial. EUROPEAN UROLOGY. 2024; 86(3)DOI:10.1016/j.eururo.2024.02.016. PMID:38490857. IF:25.200(Q1/1D).